The total burden of subclinical coronary artery disease (CAD) is significant among young adults. Serum fibroblast growth factor 23 (FGF-23) and fetuin-A are established predictors of morbidity and mortality because of cardiovascular disease. The objective of the study was to evaluate the relationship between subclinical CAD and serum FGF-23 and fetuin-A concentrations among a population of young adults.
Methods
A total of 241 subjects younger than 45 years who had undergone coronary computed tomographic angiography (CCTA) were included in the study. In 117 patients, the CCTA detected subclinical CAD; the rest of the patients had no CAD detected on CCTA.
Results
Serum FGF-23 and fetuin-A levels were significantly increased in the CAD patients as compared with the non-CAD patients (26.7 [interquartile range, 22.4-31.9] vs 15.7 [interquartile range, 13.2-18.1] pg/mL and 904.7 [interquartile range, 695.5-1021.6] vs 469.6 [331.4-660.5] mg/L, respectively; P < 0.001 for both). Furthermore, a positive correlation was identified between FGF-23 and fetuin-A levels and the total number of plaques (r = 0.21 and r = 0.28, respectively; P < 0.001 for both). In multivariate logistic regression analysis, age, smoking status, uric acid, FGF-23, and fetuin-A levels were found to be independently associated with the presence of CAD.
Conclusions
The presence of subclinical CAD is independently associated with FGF-23 and fetuin-A and could be used as novel risk markers of cardiovascular disease in the asymptomatic young adult population.
GutiérrezOM, JanuzziJL, IsakovaT, . Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009; 119: 2545–2552.
6.
BalciM, KirkpanturA, GulbayM, . Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients. Hemodial Int. 2010; 14: 425e32.
7.
MirzaMA, LarssonA, LindL, . Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009; 205: 385–390.
8.
KanbayM, NicoletaM, SelcokiY, . Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin J Am Soc Nephrol. 2010; 5: 1780e6.
9.
MasaiH, JokiN, SugiK, . A preliminary study of the potential role of FGF-23 in coronary calcification in patients with suspected coronary artery disease. Atherosclerosis. 2013; 226: 228–233.
10.
LebretonJP, JoiselF, RaoultJP, . Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest. 1979; 64: 1118–1129.
11.
CozzolinoM, GalassiA, BiondiML, . Serum fetuin-A levels link inflammation and cardiovascular calcification in hemodialysis patients. Am J Nephrol. 2006; 26: 423–429.
12.
MoriK, IkariY, JonoS, . Fetuin-A is associated with calcified coronary artery disease. Coron Artery Dis. 2010; 21: 281–285.
13.
RittigK, ThamerC, HauptA, . High plasma fetuin-A is associated with increased carotid intima-media thickness in a middle-aged population. Atherosclerosis. 2009; 207(2): 341–342.
14.
KettelerM, BongartzP, WestenfeldR, . Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003; 361: 827–833.
15.
IxJH, BiggsML, MukamalKJ, . Association of fetuin-a with incident diabetes mellitus in community-living older adults: the cardiovascular health study. Circulation. 2012; 125(19): 2316–2322.
16.
LaughlinGA, CumminsKM, WasselCL, . The association of fetuin-A with cardiovascular disease mortality in older community-dwelling adults: the Rancho Bernardo study. J Am Coll Cardiol. 2012; 59: 1688–1696.
17.
AustenWG, EdwardsJE, FryeRL, . A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation. 1975; 51: 5–40.
18.
LeberAW, BeckerA, KnezA, . Accuracy of 64-slice computed tomography to classify and quantify plaque volumes in the proximal coronary system: a comparative study using intravascular ultrasound. J Am Coll Cardiol. 2006; 47: 672–677.
19.
LeveyAS, GreeneT, BeckGJ, . Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown?J Am Soc Nephrol. 1999; 10: 2426–2439.
20.
TuzcuEM, KapadiaSR, TutarE, . High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation. 2001; 103: 2705–2710.
21.
ChenYC, LinFY, LinRH, . Relation between fetuin-A levels and fibroblast growth factor 23 with the severity of coronary artery disease measured by SYNTAX scores. Am J Cardiol. 2013; 112: 950–953.
22.
Donate-CorreaJ, Mora-FernándezC, Martínez-SanzR, . Expression of FGF23/KLOTHO system in human vascular tissue. Int J Cardiol. 2013; 165: 179–183.
23.
LimK, LuTS, MolostvovG, . Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to FGF-23. Circulation. 2012; 125: 2243–2255.
24.
GutierrezO, IsakovaT, RheeE, . Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005; 16: 2205–2215.
25.
TuñónJ, CristóbalC, TarínN, . Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease. PLoS One. 2014; 9: e95402.
26.
PertosaG, SimoneS, CicconeM, . Serum fetuin a in hemodialysis: a link between derangement of calcium-phosphorus homeostasis and progression of atherosclerosis?Am J Kidney Dis. 2009; 53: 467–474.
27.
AkyuzA, OranM, AlpsoyS, . Association between serum fetuin-A levels, carotid artery stiffness, and intima-media thickness in patients with normotensive obstructive sleep apnea syndrome. Angiology. 2013; 65: 607–613.
28.
DogruT, GencH, TapanS, . Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf). 2013; 78: 712–717.
29.
FioreCE, CelottaG, PolitiGG, . Association of high alpha2-Heremans-Schmid glycoprotein/fetuin concentration in serum and intima-media thickness in patients with atherosclerotic vascular disease and low bone mass. Atherosclerosis. 2007; 195: 110–115.
30.
WeikertC, StefanN, SchulzeMB, . Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation. 2008; 118: 2555–2562.
31.
MehrotraR, WestenfeldR, ChristensonP, . Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int. 2005; 67: 1070–1077.
32.
AubergerP, FalquerhoL, ContreresJO, . Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell. 1989; 58: 631–640.
33.
SrinivasPR, WagnerAS, ReddyLV, . Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol. 1993; 7: 1445–1455.
34.
XuY, XuM, BiY, . Serum fetuin-A is correlated with metabolic syndrome in middle-aged and elderly Chinese. Atherosclerosis. 2011; 216: 180–186.
35.
CoenG, De PaolisP, BallantiP, . Peripheral artery calcifications evaluated by histology correlate to those detected by CT: relationships with fetuin-A and FGF-23. J Nephrol. 2011; 24: 313–321.
36.
RoosM, LutzJ, SalmhoferH, . Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. Clin Endocrinol (Oxf). 2008; 68: 660–665.
37.
VoigtM, FischerDC, RimpauM, . Fibroblast growth factor (FGF)-23 and fetuin-A in calcified carotid atheroma. Histopathology. 2010; 56(6): 775–788.
